New hope for young cancer patients: experimental combo targets stubborn tumors
NCT ID NCT04890093
First seen Jan 17, 2026 · Last updated May 13, 2026 · Updated 15 times
Summary
This study tests a new drug called PEN-866 combined with two standard chemotherapy drugs (vincristine and temozolomide) in people aged 12 to 39 whose solid tumors, including Ewing sarcoma and rhabdomyosarcoma, have come back or not responded to standard treatments. The goal is to find the best dose and see if the combination can shrink tumors. Participants receive the drugs in 21-day cycles for up to 18 cycles, with regular check-ups and questionnaires about their well-being.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHABDOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Childrens National Medical Center
Washington D.C., District of Columbia, 20010, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.